Cargando…
Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance
SIMPLE SUMMARY: We used multi-omics approaches to evaluate the association of complement signature C3/C5/C3AR1/C5AR1 with tumor immune phenotypes and prognosis across various cancer types. We found that the gene signatures have deregulated expression in human malignancies and demonstrated context-de...
Autores principales: | Lawal, Bashir, Tseng, Sung-Hui, Olugbodi, Janet Olayemi, Iamsaard, Sitthichai, Ilesanmi, Omotayo B., Mahmoud, Mohamed H., Ahmed, Sahar H., Batiha, Gaber El-Saber, Wu, Alexander T. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394789/ https://www.ncbi.nlm.nih.gov/pubmed/34439277 http://dx.doi.org/10.3390/cancers13164124 |
Ejemplares similares
-
Computational and Preclinical Evidence of Anti-ischemic Properties of L-Carnitine-Rich Supplement via Stimulation of Anti-inflammatory and Antioxidant Events in Testicular Torsed Rats
por: Olugbodi, Janet Olayemi, et al.
Publicado: (2021) -
Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections
por: Muenstermann, Marcel, et al.
Publicado: (2019) -
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
por: Wang, Yu, et al.
Publicado: (2019) -
The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist
por: Li, Xaria X., et al.
Publicado: (2021) -
Down-Regulation of C3aR/C5aR Inhibits Cell Proliferation and EMT in Hepatocellular Carcinoma
por: Chen, Bendong, et al.
Publicado: (2020)